{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:34:42Z","timestamp":1791588882261,"version":"4.3.4"},"reference-count":95,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Inactivated poliovirus vaccine (IPV), available since 1955, became the first vaccine to be used to protect against poliomyelitis. While the immunogenicity of IPV to prevent paralytic poliomyelitis continues to be irrefutable, its requirement for strong containment (due to large quantities of live virus used in the manufacturing process), perceived lack of ability to induce intestinal mucosal immunity, high cost and increased complexity to administer compared to oral polio vaccine (OPV), have limited its use in the global efforts to eradicate poliomyelitis. In order to harvest the full potential of IPV, a program of work has been carried out by the Global Polio Eradication Initiative (GPEI) over the past two decades that has focused on: (1) increasing the scientific knowledge base of IPV; (2) translating new insights and evidence into programmatic action; (3) expanding the IPV manufacturing infrastructure for global demand; and (4) continuing to pursue an ambitious research program to develop more immunogenic and safer-to-produce vaccines. While the knowledge base of IPV continues to expand, further research and product development are necessary to ensure that the program priorities are met (e.g., non-infectious production through virus-like particles, non-transmissible vaccine inducing humoral and intestinal mucosal immunity and new methods for house-to-house administration through micro-needle patches and jet injectors), the discussions have largely moved from whether to how to use this vaccine most effectively. In this review, we summarize recent developments on expanding the science base of IPV and provide insight into policy development and the expansion of IPV manufacturing and production, and finally we provide an update on the current priorities.<\/jats:p>","DOI":"10.3390\/pathogens13030224","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T10:11:57Z","timestamp":1709547117000},"page":"224","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance"],"prefix":"10.3390","volume":"13","author":[{"given":"Roland W.","family":"Sutter","sequence":"first","affiliation":[{"name":"Tamayo Federal Solutions LLC, Virginia Beach, VA 23452, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Eisenhawer","sequence":"additional","affiliation":[{"name":"Polio Eradication Department, World Health Organization, 1211 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia A.","family":"Molodecky","sequence":"additional","affiliation":[{"name":"Polio Surge Capacity Support Program, The Task Force for Global Health, Inc., Decatur, GE 30030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Verma","sequence":"additional","affiliation":[{"name":"Polio Eradication Department, World Health Organization, 1211 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Okayasu","sequence":"additional","affiliation":[{"name":"Division of Healthy Environments and Population, Regional Office for the Western Pacific, World Health Organization, Manila 1000, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"ref_1","unstructured":"World Health Assembly (1988). Global Eradication of Poliomyelitis by the Year 2000. Resolutions of the 41st World Health Assembly, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.15585\/mmwr.mm7219a3","article-title":"Progress toward poliomyelitis eradication\u2014Worldwide, January 2021\u2013March 2023","volume":"72","author":"Lee","year":"2023","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_3","first-page":"1","article-title":"An evaluation of the 1954 poliomyelitis vaccine trials","volume":"45","author":"Francis","year":"1955","journal-title":"Am. J. Public Health Nation\u2019s Health"},{"key":"ref_4","first-page":"841","article-title":"Poliovirus Vaccine\u2014Inactivated","volume":"Volume 48","author":"Plotin","year":"2018","journal-title":"Plotkin\u2019s Vaccines"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1093\/clinids\/6.Supplement_2.S335","article-title":"Inactivated poliovirus vaccine: Current production methods and new developments","volume":"6","author":"Osterhaus","year":"1984","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1045-1056(05)80046-6","article-title":"Swedish inactivated polio vaccine: Laboratory standardization and clinical experience over a 30-year period","volume":"20","author":"Larsson","year":"1992","journal-title":"Biologicals"},{"key":"ref_7","first-page":"866","article-title":"Poliovirus Vaccine\u2014Live","volume":"Volume 49","author":"Plotin","year":"2018","journal-title":"Plotkin\u2019s Vaccines"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s12098-017-2586-8","article-title":"Global polio eradication\u2014Way ahead","volume":"85","author":"Bahl","year":"2018","journal-title":"Indian J. Pediatr."},{"key":"ref_9","unstructured":"Global Polio Eradication Initiative (2006). 2005 Annual Report, World Health Organization. WHO\/Polio\/06.02."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1093\/infdis\/jiu295","article-title":"Vaccine-derived polioviruses","volume":"210","author":"Burns","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_11","unstructured":"Global Polio Eradication Initiative (2013). Polio Eradication & Endgame Strategic Plan 2013\u20132018, World Health Organization."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1093\/infdis\/jiu184","article-title":"Vaccine-associated paralytic poliomyelitis: A review of the epidemiology and estimation of the global burden","volume":"210","author":"Platt","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_13","unstructured":"Global Polio Eradication Initiative (2017). Polio endgame & legacy\u2014Implementation, best practices, and lessons learned. J. Infect. Dis., 216, S1\u2013S379."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1098419","DOI":"10.3389\/fpubh.2023.1098419","article-title":"Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation","volume":"11","author":"Thompson","year":"2023","journal-title":"Front. Public Health"},{"key":"ref_15","unstructured":"World Health Organization (2020). Meeting of the Strategic Advisory Group on Immunization October 2020\u2014Conclusions and recommendations. Wkly. Epidemiol. Rec., 48, 585\u2013608."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1473-3099(20)30774-X","article-title":"Fractional dose IPV in polio eradication","volume":"21","author":"Macklin","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.vaccine.2022.03.056","article-title":"Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial","volume":"40","author":"Crothers","year":"2022","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.vaccine.2023.01.048","article-title":"Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E. coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study","volume":"41","author":"Erdem","year":"2023","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/163.1.1","article-title":"Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines","volume":"163","author":"Onorato","year":"1991","journal-title":"J. Infect. Dis."},{"key":"ref_20","first-page":"265","article-title":"Comparison of resistance of the intestinal tract to poliomyelitis vaccine (Sabin strains) in persons after naturally and experimentally acquired immunity","volume":"5","author":"Ghendon","year":"1961","journal-title":"Acta Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/oxfordjournals.aje.a009924","article-title":"Transmissibility and persistence of oral polio vaccine viruses: Implications for the global poliomyelitis eradication initiative","volume":"150","author":"Fine","year":"1999","journal-title":"Am. J. Epidemiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e001613","DOI":"10.1136\/bmjgh-2019-001613","article-title":"Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in Sweden","volume":"4","author":"Brickley","year":"2019","journal-title":"BMJ Glob. Health"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Cuba IPV Study Collaborative Group (2007). Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N. Engl. J. Med., 356, 1536\u20131544.","DOI":"10.1056\/NEJMoa054960"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1016\/j.vaccine.2023.08.055","article-title":"Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial","volume":"41","author":"Snider","year":"2023","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/jpids\/piac046","article-title":"Inactivated poliovirus vaccine closing the type 2 immunity gap in Vietnam","volume":"11","author":"Dang","year":"2022","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/oxfordjournals.aje.a120272","article-title":"Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic","volume":"76","author":"Marine","year":"1962","journal-title":"Am. J. Epidemiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.2105\/AJPH.54.8.1222","article-title":"Observed and expected poliomyelitis in the United States, 1958\u20131961","volume":"54","author":"Stickle","year":"1964","journal-title":"Am. J. Public Health Nation\u2019s Health"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1093\/infdis\/jiu060","article-title":"Switch from oral to inactivated poliovirus vaccine in Yogyakarta Province, Indonesia: Summary of coverage, immunity, and environmental surveillance","volume":"210","author":"Wahjuhono","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"A58","DOI":"10.1016\/j.vaccine.2022.02.022","article-title":"Concurrent outbreaks of circulating vaccine-derived poliovirus types 1 and 2 affecting the Republic of the Philippines and Malaysia, 2019\u20132021","volume":"41","author":"Snider","year":"2023","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(14)60934-X","article-title":"Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: An open-label, randomised controlled trial","volume":"384","author":"John","year":"2014","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1126\/science.1255006","article-title":"Polio eradication. Efficacy of inactivated poliovirus vaccine in India","volume":"345","author":"Jafari","year":"2014","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Hird, T.R., and Grassly, N.C. (2012). Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002599"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1586\/14760584.2015.1052800","article-title":"Impact of inactivated poliovirus vaccine on mucosal immunity: Implications for the polio eradication endgame","volume":"14","author":"Parker","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S1473-3099(19)30301-9","article-title":"Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: A systematic review and network meta-analysis","volume":"19","author":"Macklin","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/infdis\/jiz026","article-title":"Poliovirus Type 2 Seroprevalence Following Full- or Fractional-Dose Inactivated Poliovirus Vaccine in the Period After Sabin Type 2 Withdrawal in Sri Lanka","volume":"219","author":"Gamage","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/infdis\/jiac205","article-title":"One Full or Two Fractional Doses of Inactivated Poliovirus Vaccine for Catch-up Vaccination in Older Infants: A Randomized Clinical Trial in Bangladesh","volume":"226","author":"Aziz","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e923","DOI":"10.1016\/S2666-5247(23)00215-X","article-title":"Persistence of immunity following a single dose of inactivated poliovirus vaccine: A phase 4, open label, non-randomised clinical trial","volume":"4","author":"Sharma","year":"2023","journal-title":"Lancet Microbe"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.vaccine.2017.03.008","article-title":"Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule","volume":"35","author":"Anand","year":"2017","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1086\/651611","article-title":"Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba","volume":"201","author":"Resik","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa1202541","article-title":"Priming after a fractional dose of inactivated poliovirus vaccine","volume":"368","author":"Resik","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1056\/NEJMoa0909383","article-title":"Fractional doses of inactivated poliovirus vaccine in Oman","volume":"362","author":"Mohammed","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1016\/j.vaccine.2017.04.075","article-title":"Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan","volume":"35","author":"Saleem","year":"2017","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.15585\/mmwr.mm7247a3","article-title":"Notes from the Field: House-to-House Campaign Administration of Inactivated Poliovirus Vaccine\u2014Sokoto State, Nigeria, November 2022","volume":"72","author":"Biya","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bullo, U.F., Mehraj, J., Raza, S.M., Rasool, S., Ansari, N.N., Shaikh, A.A., Phul, Z.A., Memon, S.A., Baloch, R.I., and Baloch, Z.A. (2021). An experience of mass administration of fractional dose inactivated polio vaccine through intradermal needle-free injectors in Karachi, Sindh, Pakistan. BMC Public Health, 21.","DOI":"10.1186\/s12889-020-10041-8"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.15585\/mmwr.mm6647a4","article-title":"Fractional-dose inactivated poliovirus vaccine campaign\u2014Sindh Province, Pakistan, 2016","volume":"66","author":"Pervaiz","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.vaccine.2014.11.025","article-title":"Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: A randomized controlled trial in Cuba","volume":"33","author":"Resik","year":"2015","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Cooper, L.V., Erbeto, T.B., Danzomo, A.A., Abdullahi, H.W., Boateng, K., Adamu, U.S., Shuaib, F., Modjirom, N., Gray, E.J., and Bandyopadhyay, A.S. (2024). Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: A case control study. Lancet Infect. Dis., online ahead of print.","DOI":"10.1016\/S1473-3099(23)00688-6"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1473-3099(15)00488-0","article-title":"Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: A comparative, observer-blind, randomised, controlled trial","volume":"16","author":"Clemens","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF00156819","article-title":"Immunologic memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule","volume":"5","author":"Swartz","year":"1989","journal-title":"Eur. J. Epidemiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0140-6736(91)90480-D","article-title":"Immune response to intradermally injected inactivated poliovirus vaccine","volume":"338","author":"Samuel","year":"1991","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0264-410X(97)00293-4","article-title":"Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine","volume":"16","author":"Nirmal","year":"1998","journal-title":"Vaccine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1016\/j.ijid.2011.10.002","article-title":"Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines","volume":"16","author":"Vidor","year":"2012","journal-title":"Int. J. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1016\/j.vaccine.2013.05.104","article-title":"Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults","volume":"31","author":"Soonawala","year":"2013","journal-title":"Vaccine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(21)00497-6","article-title":"Intradermal administration of fractional doses of the inactivated poliovirus vaccine in a campaign: A pragmatic, open-label, non-inferiority trial in The Gambia","volume":"10","author":"Bashorun","year":"2022","journal-title":"Lancet Glob. Health"},{"key":"ref_55","first-page":"100235","article-title":"Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological survey","volume":"11","author":"Trueba","year":"2022","journal-title":"Lancet Reg. Health Am."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jpids\/piab091","article-title":"Immunogenicity of fractional dose inactivated poliovirus vaccine in India","volume":"11","author":"Ahmad","year":"2022","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/S0140-6736(19)30503-3","article-title":"Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: An open-label, randomised controlled trial","volume":"393","author":"Snider","year":"2019","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.1016\/j.vaccine.2015.09.039","article-title":"Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial","volume":"33","author":"Anand","year":"2015","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11894-017-0570-0","article-title":"Tropical enteropathies","volume":"19","author":"Kelly","year":"2017","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/clinids\/13.5.926","article-title":"Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review","volume":"13","author":"Patriarca","year":"1991","journal-title":"Clin. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1093\/infdis\/175.Supplement_1.S258","article-title":"The effect of diarrhea on oral poliovirus vaccine failure in Brazil","volume":"175","author":"Posey","year":"1997","journal-title":"J. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S856","DOI":"10.1093\/infdis\/jiab372","article-title":"Intestinal Biopsies for the Evaluation of Environmental Enteropathy and Environmental Enteric Dysfunction","volume":"224","author":"Hodges","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41385-018-0036-1","article-title":"Pathophysiology of environmental enteric dysfunction and its impact on oral vaccine efficacy","volume":"11","author":"Marie","year":"2018","journal-title":"Mucosal Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S1473-3099(20)30693-9","article-title":"Fractional dose compared with standard dose inactivated poliovirus vaccine in children: A systematic review and meta-analysis","volume":"21","author":"Mashunye","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1093\/infdis\/175.Supplement_1.S37","article-title":"Eradication of wild poliovirus from the Americas: Acute flaccid paralysis surveillance, 1988\u20131995","volume":"175","author":"Hersh","year":"1997","journal-title":"J. Infect. Dis."},{"key":"ref_66","first-page":"1","article-title":"Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"49","author":"Prevots","year":"2000","journal-title":"MMWR Recomm. Rep."},{"key":"ref_67","unstructured":"World Health Organization (2012). Meeting of the Strategic Advisory Group of Experts on immunization, April 2012\u2014Conclusions and recommendations. Wkly. Epidemiol. Rec., 87, 201\u2013216."},{"key":"ref_68","unstructured":"(2024, January 01). Global Vaccine Alliance to Deploy Six-in-One Vaccine to Lower-Income Countries, Establish Innovative Mechanisms to Protect against Future Epidemic Threats. Available online: https:\/\/www.gavi.org\/news\/media-room\/global-vaccine-alliance-deploy-six-one-vaccine-lower-income-countries."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"859","DOI":"10.15585\/mmwr.mm6533a5","article-title":"Fractional-dose inactivated poliovirus vaccine immunization campaign\u2014Telangana State, India, June 2016","volume":"65","author":"Bahl","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.vaccine.2019.12.059","article-title":"Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability","volume":"38","author":"Daly","year":"2020","journal-title":"Vaccine"},{"key":"ref_71","unstructured":"World Health Organization (2023). Meeting of the Strategic Advisory Group of Experts on Immunization, March 2023: Conclusions and recommendations. Wkly. Epidemiol. Rec., 98, 239\u2013256."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"A113","DOI":"10.1016\/j.vaccine.2022.03.027","article-title":"Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks","volume":"41","author":"Estivariz","year":"2023","journal-title":"Vaccine"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Bandyopadhyay, A.S., Lopez Cavestany, R., Blake, I.M., Macklin, G., Cooper, L., Grassly, N., Nery, A.L.M.D.S., and Mach, O. (2023). Use of inactivated poliovirus vaccine for poliovirus outbreak response. Lancet Infect. Dis., online ahead of print.","DOI":"10.1016\/S1473-3099(23)00505-4"},{"key":"ref_74","unstructured":"World Health Organization (2024, January 01). Introduction of New Vaccines. Available online: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/essential-programme-on-immunization\/implementation\/introduction-of-new-vaccines."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"S459","DOI":"10.1093\/infdis\/jiu128","article-title":"Affordable inactivated poliovirus vaccine: Strategies and progress","volume":"210","author":"Okayasu","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_76","unstructured":"World Health Organization (2022). WHO Action Plan for Poliovirus Containment, World Health Organization. [4th ed.]. Available online: https:\/\/polioeradication.org\/wp-content\/uploads\/2022\/07\/WHO-Global-Action-Plan-for-Poliovirus-Containment-GAPIV.pdf."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.vaccine.2014.11.015","article-title":"Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan","volume":"34","author":"Shimizu","year":"2016","journal-title":"Vaccine"},{"key":"ref_78","unstructured":"(2024, January 01). Available online: https:\/\/www.thelancet.com\/cms\/10.1016\/j.lanwpc.2021.100133\/attachment\/8c660f65-c236-4b2e-a8ba-1f6a42983adc\/mmc4.pdf."},{"key":"ref_79","unstructured":"World Health Assembly (2008, January 19\u201324). Resolutions and Decisions. WHA61.1. Poliomyelitis: Mechanism for management of potential risks to eradication. Proceedings of the Sixty-First World Health Assembly, Geneva, Switzerland."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/cid\/cix116","article-title":"Next generation inactivated poliovirus vaccine: The future has arrived","volume":"64","author":"Sutter","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.biologicals.2016.08.005","article-title":"Development of inactivated poliovirus vaccine from Sabin strains: A progress report","volume":"44","author":"Okayasu","year":"2016","journal-title":"Biologicals"},{"key":"ref_82","unstructured":"United Nations Children\u2019s Fund (2024, January 01). Available online: https:\/\/www.unicef.org\/supply\/media\/17981\/file\/IPV-vaccine-prices-17-07-2023.pdf."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Cheng, L., Wang, Y., and Du, J. (2020). Human Papillomavirus Vaccines: An Updated Review. Vaccines, 8.","DOI":"10.3390\/vaccines8030391"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Fox, H., Knowlson, S., Minor, P.D., and Macadam, A.J. (2017). Genetically Thermo-Stabilised, Immunogenic Poliovirus Empty Capsids; a Strategy for Non-replicating Vaccines. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006117"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41467-017-00090-w","article-title":"Plant-made polio type 3 stabilized VLPs\u2014A candidate synthetic polio vaccine","volume":"8","author":"Marsian","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41541-020-00267-3","article-title":"Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines","volume":"6","author":"Bahar","year":"2021","journal-title":"npj Vaccines"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Bahar, M.W., Nasta, V., Fox, H., Sherry, L., Grehan, K., Porta, C., Macadam, A.J., Stonehouse, N.J., Rowlands, D.J., and Fry, E.E. (2022). A conserved glutathione binding site in poliovirus is a target for antivirals and vaccine stabilisation. Commun. Biol., 5.","DOI":"10.1038\/s42003-022-04252-5"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Adeyemi, O.O., Nicol, C., Stonehouse, N.J., and Rowlands, D.J. (2017). Increasing type 1 poliovirus capsid stability by thermal selection. J. Virol., 91.","DOI":"10.1128\/JVI.01586-16"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Sherry, L., Grehan, K., Snowden, J.S., Knight, M.L., Adeyemi, O.O., Rowlands, D.J., and Stonehouse, N.J. (2020). Comparative molecular biology approaches for the production of Poliovirus Virus-Like Particles using Pichia pastoris. mSphere, 5.","DOI":"10.1128\/mSphere.00838-19"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Sherry, L., Grehan, K., Swanson, J.J., Bahar, M.W., Porta, C., Fry, E.E., Stuart, D.I., Rowlands, D.J., and Stonehouse, N.J. (2022). Production and characterisation of stabilised PV-3 Virus-like Particles using Pichia pastoris. Viruses, 14.","DOI":"10.1101\/2022.09.16.508282"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Sherry, L., Swanson, J.J., Grehan, K., Xu, H., Uchida, M., Jones, I.M., Stonehouse, N.J., and Rowlands, D.J. (2023). Protease-independent production of Poliovirus Virus-like Particles in Pichia pastoris: Implications for efficient vaccine development and Insights into capsid assembly. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.04300-22"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Clements, J.D., and Norton, E.B. (2018). The Mucosal Vaccine Adjuvant LT(R192G\/L211A) or dmLT. mSphere, 3.","DOI":"10.1128\/mSphere.00215-18"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Knowlson, S., Burlison, J., Giles, E., Fox, H., Macadam, A.J., and Minor, P.D. (2015). New strains intended for the production of Inactivated Polio Vaccine at low-containment after eradication. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005316"},{"key":"ref_94","unstructured":"World Health Organization (2024, January 01). CAG-TC3-20180630-EN.pdf. Available online: https:\/\/polioeradication.org\/."},{"key":"ref_95","unstructured":"World Health Organization (2022). Polio vaccines: WHO position paper\u2014June 2022. Wkly. Epidemiol. Rec., 97, 277\u2013300."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/3\/224\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:09:06Z","timestamp":1760105346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/3\/224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":95,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["pathogens13030224"],"URL":"https:\/\/doi.org\/10.3390\/pathogens13030224","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]}}}